Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 27 June 2003:
Vol. 300. no. 5628, pp. 2036 - 2039
DOI: 10.1126/science.1086916
Prev | Table of Contents | Next

Policy Forum

MEDICINE:
Enhanced: The Need for a Global HIV Vaccine Enterprise

Richard D. Klausner, Anthony S. Fauci, Lawrence Corey, Gary J. Nabel, Helene Gayle, Seth Berkley, Barton F. Haynes, David Baltimore, Chris Collins, R. Gordon Douglas, Jose Esparza, Donald P. Francis, N. K. Ganguly, Julie Louise Gerberding, Margaret I. Johnston, Michel D. Kazatchkine, Andrew J. McMichael, Malegapuru W. Makgoba, Giuseppe Pantaleo, Peter Piot, Yiming Shao, Edmund Tramont, Harold Varmus, Judith N. Wasserheit

A new collaborative model of research is needed to increase resources, to prioritize the R&D agenda of the major public- and private-sector stakeholders, and ultimately to increase the probability and shorten the time to development of effective HIV vaccines for global use. The thrust of our proposal is (i) to increase the scale and organization for solving science problems and developing novel HIV vaccine approaches; (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.

R. D. Klausner and H. Gayle are at the Bill and Melinda Gates Foundation, Seattle, WA 98102, USA. A. S. Fauci is director of the National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA; E. C. Tramont is director of the Division of AIDS (DAIDS), NIAID, NIH; G. Nabel is director of the Vaccine Research Center, NIAID, and M. I. Johnston is associate director of the Vaccine and Prevention Research Program, DAIDS. L. Corey and J. N. Wasserheit are with the HIV Vaccine Trials Network, Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, and the University of Washington, Seattle, WA 98109, USA; L. Corey is also in the Department of Laboratory Medicine, University of Washington. S. Berkley is with the International AIDS Vaccine Initiative, New York, NY 10038, USA. B. F. Haynes is at the Duke University School of Medicine, Durham, NC 27710, USA. D. Baltimore is at the California Institute of Technology, Pasadena, CA 91125, USA. C. Collins is at the AIDS Vaccine Advocacy Coalition, New York, NY 10011, USA. R. G. Douglas Jr. is at the Sequella Global Tuberculosis Foundation, Rockville, MD 20850, USA. J. Esparza is coordinator of the HIV Vaccine Initiative of the World Health Organization-Joint United Nations Programme on HIV/AIDS (WHO-UNAIDS), Geneva 27, Switzerland. D. P. Francis is at the VaxGen, Inc., Brisbane, CA 94005, USA. N. K. Ganguly is in the Indian Council of Medical Research, New Delhi 110029, India. J. L. Gerberding is at the Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. M. D. Kazatchkine is at the Agence Nationale de Recherches sur le Side (ANRS), Paris 75013, France. A. J. McMichael is at the MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK. M. W. Makgoba is at the University of Natal, Durban 4041, South Africa. G. Pantaleo is in the Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne CH-1011, Switzerland. P. Piot is with UNAIDS, Geneva 27, Switzerland. Y. Shao is at the National Center for AIDS/STD Control and Prevention, Beijing 100050, China. H. Varmus is at the Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications.
S. Bryson, J.-P. Julien, R. C. Hynes, and E. F. Pai (2009)
J. Virol. 83, 11862-11875
   Abstract »    Full Text »    PDF »
Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents.
M. J. Boaz, P. Hayes, T. Tarragona, L. Seamons, A. Cooper, J. Birungi, P. Kitandwe, A. Semaganda, P. Kaleebu, G. Stevens, et al. (2009)
Clin. Vaccine Immunol. 16, 147-155
   Abstract »    Full Text »    PDF »
The discovery value of "Big Science".
J. Esparza and T. Yamada (2007)
J. Exp. Med. 204, 701-704
   Abstract »    Full Text »    PDF »
Control of Simian Immunodeficiency Virus SIVmac239 Is Not Predicted by Inheritance of Mamu-B*17-Containing Haplotypes.
J. A. Wojcechowskyj, L. J. Yant, R. W. Wiseman, S. L. O'Connor, and D. H. O'Connor (2007)
J. Virol. 81, 406-410
   Abstract »    Full Text »    PDF »
Immunostimulatory combinations: designing the next generation of vaccine adjuvants.
R. S. Kornbluth and G. W. Stone (2006)
J. Leukoc. Biol. 80, 1084-1102
   Abstract »    Full Text »    PDF »
Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World.
I. Serdobova and M.-P. Kieny (2006)
Am J Public Health 96, 1554-1559
   Abstract »    Full Text »    PDF »
Structure-Function Analysis of the Epitope for 4E10, a Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody.
F. M. Brunel, M. B. Zwick, R. M. F. Cardoso, J. D. Nelson, I. A. Wilson, D. R. Burton, and P. E. Dawson (2006)
J. Virol. 80, 1680-1687
   Abstract »    Full Text »    PDF »
Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1.
S. Beddows, N. Schulke, M. Kirschner, K. Barnes, M. Franti, E. Michael, T. Ketas, R. W. Sanders, P. J. Maddon, W. C. Olson, et al. (2005)
J. Virol. 79, 8812-8827
   Abstract »    Full Text »    PDF »
Effect of CD8+ Lymphocyte Depletion on Virus Containment after Simian Immunodeficiency Virus SIVmac251 Challenge of Live Attenuated SIVmac239{Delta}3-Vaccinated Rhesus Macaques.
J. E. Schmitz, R. P. Johnson, H. M. McClure, K. H. Manson, M. S. Wyand, M. J. Kuroda, M. A. Lifton, R. S. Khunkhun, K. J. McEvers, J. Gillis, et al. (2005)
J. Virol. 79, 8131-8141
   Abstract »    Full Text »    PDF »
Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1.
M. B. Zwick, R. Jensen, S. Church, M. Wang, G. Stiegler, R. Kunert, H. Katinger, and D. R. Burton (2005)
J. Virol. 79, 1252-1261
   Abstract »    Full Text »    PDF »
Health and economic benefits of an accelerated program of research to combat global infectious diseases.
Global IDEA Scientific Advisory Committee (2004)
Can. Med. Assoc. J. 171, 1203-1208
   Full Text »    PDF »
Research and Development of New Vaccines Against Infectious Diseases.
M. P. Kieny, J.-L. Excler, and M. Girard (2004)
Am J Public Health 94, 1931-1935
   Abstract »    Full Text »    PDF »
Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative.
T. J Tucker and G. Mazithulela (2004)
BMJ 329, 454-456
   Full Text »    PDF »
Mapping Sites of Positive Selection and Amino Acid Diversification in the HIV Genome: An Alternative Approach to Vaccine Design?.
T. de Oliveira, M. Salemi, M. Gordon, A.-M. Vandamme, E. J. van Rensburg, S. Engelbrecht, H. M. Coovadia, and S. Cassol (2004)
Genetics 167, 1047-1058
   Abstract »    Full Text »    PDF »
Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins.
H.-X. Liao, S. M. Alam, J. R. Mascola, J. Robinson, B. Ma, D. C. Montefiori, M. Rhein, L. L. Sutherland, R. Scearce, and B. F. Haynes (2004)
J. Virol. 78, 5270-5278
   Abstract »    Full Text »    PDF »
Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination.
J. Stebbing, B. Gazzard, S. Patterson, M. Bower, D. Perumal, M. Nelson, A. McMichael, G. Ogg, A. Epenetos, F. Gotch, et al. (2004)
Blood 103, 1791-1795
   Abstract »    Full Text »    PDF »
Simian Immunodeficiency Virus Promoter Exchange Results in a Highly Attenuated Strain That Protects against Uncloned Challenge Virus.
P. Blancou, N. Chenciner, R. H. T. Fang, V. Monceaux, M.-C. Cumont, D. Guetard, B. Hurtrel, and S. Wain-Hobson (2004)
J. Virol. 78, 1080-1092
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)